Endonovo Therapeutics (ENDV)
(Delayed Data from OTC)
$0.00 USD
0.00 (0.00%)
Updated Aug 14, 2024 03:35 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Endonovo Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 0 | 0 | 0 | 0 | 0 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 0 | 0 | 0 | 0 | 0 |
Total Current Assets | 0 | 0 | 0 | 0 | 0 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 1 | 1 | 2 | 3 | 3 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 1 | 1 | 2 | 3 | 3 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 7 | 7 | 7 | 7 | 7 |
Accounts Payable | 1 | 1 | 1 | 1 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 5 | 4 | 3 | 2 | 1 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 12 | 22 | 7 | 8 | 15 |
Total Current Liabilities | 25 | 33 | 18 | 17 | 24 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 25 | 33 | 18 | 17 | 24 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 44 | 43 | 41 | 39 | 32 |
Retained Earnings | -68 | -75 | -56 | -53 | -53 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -24 | -32 | -16 | -14 | -21 |
Total Liabilities & Shareholder's Equity | 1 | 1 | 2 | 3 | 3 |
Total Common Equity | -24 | -32 | -16 | -14 | -21 |
Shares Outstanding | 318.70 | 219.70 | 74.50 | 24.50 | 1.10 |
Book Value Per Share | -0.08 | -0.15 | -0.21 | -0.59 | -18.64 |
Fiscal Year End for Endonovo Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | -99,999 | 0 | 0 | 0 |
Receivables | NA | NA | 0 | 0 | 0 |
Notes Receivable | NA | NA | 0 | 0 | 0 |
Inventories | NA | NA | 0 | 0 | 0 |
Other Current Assets | NA | NA | 0 | 0 | 0 |
Total Current Assets | NA | NA | 0 | 0 | 0 |
Net Property & Equipment | NA | NA | 0 | 0 | 0 |
Investments & Advances | NA | NA | 0 | 0 | 0 |
Other Non-Current Assets | NA | NA | 0 | 0 | 0 |
Deferred Charges | NA | NA | 0 | 0 | 0 |
Intangibles | NA | NA | 1 | 1 | 1 |
Deposits & Other Assets | NA | NA | 0 | 0 | 0 |
Total Assets | NA | NA | 1 | 1 | 1 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | NA | 7 | 7 | 7 |
Accounts Payable | NA | NA | 1 | 1 | 1 |
Current Portion Long-Term Debt | NA | NA | 0 | 0 | 0 |
Current Portion Capital Leases | NA | NA | 0 | 0 | 0 |
Accrued Expenses | NA | NA | 5 | 4 | 4 |
Income Taxes Payable | NA | NA | 0 | 0 | 0 |
Other Current Liabilities | NA | NA | 12 | 11 | 11 |
Total Current Liabilities | NA | NA | 25 | 24 | 23 |
Mortgages | NA | NA | 0 | 0 | 0 |
Deferred Taxes/Income | NA | NA | 0 | 0 | 0 |
Convertible Debt | NA | NA | 0 | 0 | 0 |
Long-Term Debt | NA | NA | 0 | 0 | 0 |
Non-Current Capital Leases | NA | NA | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | NA | 0 | 0 | 0 |
Total Liabilities | NA | NA | 25 | 24 | 23 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | NA | 0 | 0 | 0 |
Common Stock (Par) | NA | NA | 0 | 0 | 0 |
Capital Surplus | NA | NA | 44 | 44 | 44 |
Retained Earnings | NA | NA | -68 | -67 | -66 |
Other Equity | NA | NA | 0 | 0 | 0 |
Treasury Stock | NA | NA | 0 | 0 | 0 |
Total Shareholder's Equity | NA | NA | -24 | -23 | -22 |
Total Liabilities & Shareholder's Equity | NA | NA | 1 | 1 | 1 |
Total Common Equity | 0 | 0 | -24 | -23 | -22 |
Shares Outstanding | 396.80 | 349.30 | 318.70 | 318.20 | 278.80 |
Book Value Per Share | 0.00 | 0.00 | -0.08 | -0.07 | -0.08 |